Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres.
Vaccinating children at day-care may be a cost-effective approach for improving influenza immunization rates in this high-risk group. This study uses influenza attack-rate data from a randomized, blinded, placebo-controlled clinical trial of live-attenuated influenza vaccine, trivalent in day-care centres from two consecutive influenza seasons, one with a moderate attack rate (H1N1 dominant) and one with a high attack rate (H3N2 dominant). Costs were measured in US dollars. In the moderate attack-rate season (vaccinated, 2.2%; placebo, 13.4%), vaccination saved US$ 5.47 per child in societal costs. In the high attack-rate season (vaccinated, 4.7%; placebo, 32.1%), vaccination led to a societal costs savings of US$ 144.44 per child.
Hibbert
Clare L
CL
RTI Health Solutions, Williams House, Manchester Science Park, Lloyd Street North, Manchester M15 6SE, United Kingdom. hibbert@rti.org
Piedra
Pedro A
PA
McLaurin
Kimmie K
KK
Vesikari
Timo
T
Mauskopf
Josephine
J
Mahadevia
Parthiv J
PJ
D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care; D006801:Humans; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000191:economics* / Q000276:immunology*; D007251:Influenza, Human / Q000191:economics / Q000276:immunology / Q000517:prevention & control*; D012578:Schools, Nursery; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014613:Vaccines, Attenuated / Q000191:economics / Q000276:immunology*
D007252:Influenza Vaccines; D014613:Vaccines, Attenuated